BMY (STOCKS)
Bristol-Myers Squibb Co.
$64.838700
+1.138700 (+1.79%)
Prev close: $63.700000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Christopher S. Boerner
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $132,061.20M
- Employees
- 34,100
- P/E (TTM)
- 14.03
- P/B (TTM)
- 5.83
- Dividend Yield
- 394.03%
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
8
Buy
19
Hold
2
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$2.04 | $1.60 | +0.4362 | +27.20% |
|
Mar 2026 (Q1)
|
$1.58 | $1.43 | +0.1489 | +10.40% |
|
Dec 2025 (Q4)
|
$1.26 | $1.13 | +0.1335 | +11.85% |
|
Sep 2025 (Q3)
|
$1.63 | $1.52 | +0.1056 | +6.93% |
Financial Statements
| Revenues | $49.19B |
| Benefits Costs and Expenses | $37.28B |
| Cost Of Revenue | $14.68B |
| Costs And Expenses | $37.28B |
| Gross Profit | $34.51B |
| Operating Expenses | $22.60B |
| Selling, General, and Administrative Expenses | $7.41B |
| Research and Development | $10.72B |
| Other Operating Expenses | $4.46B |
| Operating Income/Loss | $11.91B |
| Income/Loss Before Equity Method Investments | $11.73B |
| Income/Loss From Continuing Operations After Tax | $9.28B |
| Income/Loss From Continuing Operations Before Tax | $11.91B |
| Income/Loss From Equity Method Investments | $179.00M |
| Income Tax Expense/Benefit | $2.63B |
| Income Tax Expense/Benefit, Deferred | -$785.00M |
| Net Income/Loss | $9.27B |
| Net Income/Loss Attributable To Noncontrolling Interest | -$8.00M |
| Net Income/Loss Attributable To Parent | $9.28B |
| Net Income/Loss Available To Common Stockholders, Basic | $9.28B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $4.56 |
| Diluted Earnings Per Share | $4.54 |
| Basic Average Shares | 4,076,000,000 |
| Diluted Average Shares | 4,087,000,000 |
| Assets | $87.63B |
| Current Assets | $28.58B |
| Accounts Receivable | $10.55B |
| Inventory | $2.74B |
| Other Current Assets | $15.29B |
| Noncurrent Assets | $59.06B |
| Fixed Assets | $7.79B |
| Intangible Assets | $17.39B |
| Other Non-current Assets | $33.88B |
| Liabilities | $65.32B |
| Current Liabilities | $18.66B |
| Accounts Payable | $4.16B |
| Wages | $881.00M |
| Other Current Liabilities | $13.62B |
| Noncurrent Liabilities | $46.66B |
| Long-term Debt | $42.86B |
| Other Non-current Liabilities | $3.80B |
| Equity | $22.32B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $22.32B |
| Liabilities And Equity | $87.63B |
| Net Cash Flow From Operating Activities | $12.78B |
| Net Cash Flow From Operating Activities, Continuing | $12.78B |
| Net Cash Flow From Investing Activities | -$4.91B |
| Net Cash Flow From Investing Activities, Continuing | -$4.91B |
| Net Cash Flow From Financing Activities | -$11.71B |
| Net Cash Flow From Financing Activities, Continuing | -$11.71B |
| Exchange Gains/Losses | -$57.00M |
| Net Cash Flow | -$3.89B |
| Net Cash Flow, Continuing | -$3.83B |
| Comprehensive Income/Loss | $9.54B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$7.00M |
| Comprehensive Income/Loss Attributable To Parent | $9.55B |
| Other Comprehensive Income/Loss | $264.00M |